Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Repare Therapeutics Inc (RPTX)

Repare Therapeutics Inc (RPTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,280
  • Shares Outstanding, K 42,986
  • Annual Sales, $ 53,480 K
  • Annual Income, $ -84,690 K
  • EBIT $ -78 M
  • EBITDA $ -82 M
  • 60-Month Beta 1.02
  • Price/Sales 1.71
  • Price/Cash Flow N/A
  • Price/Book 0.79

Options Overview Details

View History
  • Implied Volatility 129.21% (+23.65%)
  • Historical Volatility 88.18%
  • IV Percentile 19%
  • IV Rank 12.07%
  • IV High 688.68% on 07/17/25
  • IV Low 52.44% on 11/19/25
  • Expected Move (DTE 15) 0.49 (22.11%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 518
  • Volume Avg (30-Day) 1,896
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 11,913
  • Open Int (30-Day) 10,330
  • Expected Range 1.74 to 2.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +56.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.65 +35.15%
on 11/14/25
2.30 -3.04%
on 11/18/25
+0.45 (+25.28%)
since 11/04/25
3-Month
1.65 +35.15%
on 11/14/25
2.30 -3.04%
on 11/18/25
+0.54 (+31.95%)
since 09/04/25
52-Week
0.89 +150.56%
on 04/14/25
4.07 -45.20%
on 12/11/24
-0.67 (-23.10%)
since 12/04/24

Most Recent Stories

More News
Halper Sadeh LLC Encourages THS, RPTX, AXTA Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

RPTX : 2.23 (+2.76%)
AXTA : 29.26 (-2.47%)
THS : 23.73 (-0.88%)
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - RPTX, AXTA, WTG and SEMR

NEW YORK , Nov. 27, 2025 /PRNewswire/ -- We wish you a Happy Thanksgiving and Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"),...

SEMR : 11.84 (unch)
RPTX : 2.23 (+2.76%)
AXTA : 29.26 (-2.47%)
WTG : 10.12 (unch)
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering...

RPTX : 2.23 (+2.76%)
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

SEE : 42.28 (-0.45%)
MRSN : 27.47 (-1.36%)
RPTX : 2.23 (+2.76%)
CDTX : 220.50 (-0.22%)
RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

RPTX : 2.23 (+2.76%)
Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Nov. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

RPTX : 2.23 (+2.76%)
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

- Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 2026 - ...

RPTX : 2.23 (+2.76%)
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy...

RPTX : 2.23 (+2.76%)
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Entered into worldwide licensing agreement with Debiopharm for lunresertib Evaluating strategic alternatives to maximize shareholder value ...

RPTX : 2.23 (+2.76%)
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

/CNW/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies...

ONCY : 0.9807 (+8.19%)
RPTX : 2.23 (+2.76%)
IMRX : 6.69 (-0.74%)
ONC.TO : 1.42 (+2.16%)
RNXT : 0.9500 (+5.04%)
CRGX : 4.47 (-1.54%)

Business Summary

Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare...

See More

Key Turning Points

3rd Resistance Point 2.37
2nd Resistance Point 2.30
1st Resistance Point 2.27
Last Price 2.23
1st Support Level 2.17
2nd Support Level 2.10
3rd Support Level 2.07

See More

52-Week High 4.07
Fibonacci 61.8% 2.85
Fibonacci 50% 2.48
Last Price 2.23
Fibonacci 38.2% 2.10
52-Week Low 0.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar